Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Trump Administration Seeks to Hike Life Sciences Industry’s FDA User Fees Paid to Help Review, Approve Medical Advancements

Washington, DC, April 20, 2017 — Thomas M. Burton reported in The Wall Street Journal that a bipartisan bill in Congress calls for sharp increases in user fees paid by medical industries to the Food and Drug Administration (FDA) to bear the cost of reviewing brand-name and generic drugs, medical devices and a type of generics called biosimilars.

The total base fees for prescription drugs to be collected for fiscal year 2018 under the legislation would be about $878.8 million, up 22% from the current fiscal year’s amount of $718.7 million, according to congressional aides.

The payments from industry have previously accounted for 70% of the FDA’s brand-name drug review budget, 36% of the medical device review budget, 75% of the budget for generic drug reviews and 29% of that for biosimilars, which mimic complex biological drugs.

Industry fees for medical products total about $1.3 billion in the current FDA budget of about $4.8 billion.

Every five years, Congress reauthorizes the payments of user fees, which are designed to speed drug approvals without unduly burdening U.S. taxpayers.

So far, the draft bill made public by the leadership of both parties has been relatively lacking in controversy, but that could change.

The dollar amounts in the bill were negotiated by the FDA with the industries involved.

However, the issue got more complicated last month when the Trump administration said it planned to nearly double, to more than $2 billion, the user fees collected from the medical industry.

For Burton’s full story, click here.